When is it safe to stop immunotherapy in MOGAD, and who relapses after discontinuation?
MOGAD Discontinuation
2026Treatment Discontinuation in MOGAD
Is the efficacy and safety of ponesimod maintained over 5 years of extended treatment in relapsing MS, and does switching from teriflunomide to ponesimod sustain disease control?
OPTIMUM-LTE
Long-term safety and efficacy of ponesimod in participants with relapsing multiple sclerosis: results from the phase 3 OPTIMUM 5-year long term extension study
Journal of Neurology · 2026
Bottom Line: In the open-label OPTIMUM long-term extension, ponesimod 20 mg maintained low relapse rates and sustained disease control over 5 years in relapsing MS with no new safety signals; participants who switched from teriflunomide to ponesimod also had low relapse activity, though continuous ponesimod achieved higher NEDA-3 (17.5% vs 7.5%).